Th1/2 Immune Response Signature Predicts Outcome after Dose-Dense Immunochemotherapy in Patients with High Risk Diffuse Large B-Cell Lymphoma - Results from Nordic Lymphoma Group Trials

Matias Autio, Suvi-Katri Leivonen, Judit Meszaros Jorgensen, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Harald Holte, Sirpa Leppä

Forskningsoutput: TidskriftsbidragMötesabstraktPeer review

Originalspråkengelska
Artikelnummer4008
TidskriftBlood
Volym130
Antal sidor2
ISSN0006-4971
StatusPublicerad - 7 dec 2017
MoE-publikationstypEj behörig
Evenemang59th Annual Meeting of the American-Society-of-Hematology (ASH) - Atlanta, Gabon
Varaktighet: 9 dec 201712 dec 2017

Citera det här